MAGE-A11 (E2F1K) Rabbit mAb #99421
- WB
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 55 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
Melanoma-associated antigen-11 (MAGE-A11) is a CTA that belongs to the type I MAGE family of proteins. In normal human tissues, MAGE-A11 expression is largely restricted to the placenta and germline cells of the testis (4). Like other type I MAGE family members, however, MAGE-A11 expression is often upregulated in many different types of human cancers, including lung cancer, head and neck squamous cell carcinoma, and bladder cancer (5-7). Research studies have demonstrated that MAGE-A11 broadly functions as an oncogene by complexing with the HUWE1 E3 ubiquitin ligase. This molecular complex promotes the aberrant ubiquitin-dependent proteasomal degradation of PCF11 and subsequent dysregulation of 3' UTR processing of mRNA transcripts encoding core components of oncogenic and tumor suppressor signaling pathways (4). Given the oncogenic role of MAGE-A11 in numerous cancer types and its restricted expression pattern, there is interest in targeting antigenic epitopes of MAGE-A11 presented in the context of class I MHC alleles using engineered TCRs (8,9).
- Caballero, O.L. and Chen, Y.T. (2009) Cancer Sci 100, 2014-21.
- De Smet, C. et al. (1999) Mol Cell Biol 19, 7327-35.
- Gjerstorff, M.F. et al. (2015) Oncotarget 6, 15772-87.
- Yang, S.W. et al. (2020) Mol Cell 77, 1206-1221.e7.
- Choudhary, M. et al. (2014) Appl Biochem Biotechnol 174, 1188-200.
- Jia, S. et al. (2020) Cancer Manag Res 12, 1427-1435.
- Mohsenzadegan, M. et al. (2022) Sci Rep 12, 599.
- Zhang, J. et al. (2017) J Immunother 40, 211-220.
- Wu, Y. et al. (2020) Carcinogenesis 41, 894-903.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.